1. What Happened? H1 2025 Earnings Announcement

Seegene Medtech announced its H1 2025 earnings on August 14, 2025, reporting revenue of KRW 12.6 billion, operating profit of KRW 1.9 billion, and net profit of KRW 1.1 billion, significantly exceeding market expectations.

2. Why This Performance? Key Business Growth and Improved Fundamentals

This surprising performance is attributed to the growth of the medical device business and the stable contribution of the electric energy business. In particular, the entry into the dental implant business and the expansion of the new bone graft material line served as growth drivers. Furthermore, strengthened financial soundness led to a successful turnaround.

  • Medical Device Business: Launch of dental implant business, expansion of the new ‘Velo’ bone graft material line.
  • Electric Energy Business: Participation in Smart Grid, AMI, and EV charging infrastructure projects.
  • Financial Improvement: Decrease in debt ratio, increase in total equity.

3. What’s Next? Investment Strategy and Considerations

The positive earnings announcement is expected to provide short-term momentum for stock prices. However, investors should be aware of a few points.

  • Discrepancy between Preliminary and Reported Revenue: Clarification is needed regarding the difference between KRW 12.6 billion and KRW 24.4 billion.
  • Past Financial Burden: Accumulated deficit remains a risk factor.
  • Past Management Issues: Consider past negative issues such as breach of trust allegations.

4. What Should Investors Do? Action Plan

Short-term investors should closely monitor stock price trends following the announcement and check the performance of each business segment. Long-term investors should focus on securing sustainable growth drivers, improving the financial structure, and enhancing management transparency.